AnalystBook Research · Company Intelligence

UNITEDHEALTH GROUP INC

UNHNYSE

Built from UNITEDHEALTH GROUP INC's own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

UnitedHealth grew revenue, but earnings declined.

The read at a glance✓ Audited against SEC data
  • Business mixUnitedHealthcare, OptumNote
  • Revenue$447.57B, +11.8%OK
  • Net income$12.06B, -16.3%Watch
  • FCF$16.08BNote
  • Buybacks$5.55B, -38.4%Note
  • Altman/Beneish/EQGrey Z; M no flag; EQ safeNote
  • Insiders0 purchases / 2 salesWatch

Business

UnitedHealth reports UnitedHealthcare and Optum-related rows across benefits, pharmacy, care delivery, and information services.

Where the revenue comes from

Fiscal 2025, as UNITEDHEALTH GROUP INC reports it. History and quarterly detail are in the app.

  • Products$53.4B
  • Services$38.0B

Leadership changes

From UNITEDHEALTH GROUP INC's own filings, the day they're filed.

  • Dennis Stankiewicz · Chief Accounting Officer · appointmenteff. 2026-03-02
  • Scott Gottlieb · director · appointmenteff. 2025-11-18
  • Wayne S. DeVeydt · Chief Financial Officer · appointmenteff. 2025-09-02

Latest filings

  • 10-Q · Quarterly report2026-08-10
  • 8-K · Company announcement2026-07-16
  • 8-K · Company announcement2026-06-05
  • 8-K · Company announcement2026-05-11
  • 10-Q · Quarterly report2026-05-05
In the full recordFree for 14 days
  • What changed🔒
  • Insider signal🔒
  • Growth quality🔒
  • Margins & accounting🔒
  • Capital allocation🔒
  • Real risks🔒
  • The long arc🔒
  • Company history🔒
  • Main tension🔒
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about UNITEDHEALTH GROUP INC, every answer cited to the official filings🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

14-day free trial, no credit card. For research purposes only; not investment advice.